Sanofi launches dengue immunisation program in Brazil
pharmafile | August 15, 2016 | News story | Research and Development, Sales and Marketing | Brazil, Sanofi, Sanofi Pasteur, Vaccine, dengue, immunisation, vaccines
Sanofi has announced that it has initiated the first dengue immunisation public program in the Americas, with 500,000 individuals set to receive Dengvaxia dengue vaccine over the next three weeks.
The program will first reach people in the Paraná state of Brazil. Home to 10 million people, 55,000 cases of dengue were reported, costing the state around €91 million in related healthcare expenses.
Michele Caputo Neto, Paraná health secretary, comments: “For the public immunisation program being launched today, we have used our extensive dengue surveillance data to ensure that we are targeting people at highest risk of disease. We will vaccinate all individuals 15-27 years of age in 28 municipalities and 9-44 years of age in the two municipalities with the top dengue burden in our State over the next three weeks.”
Sanofi, along with its specialised vaccines unit Sanofi Pasteur, launched the world’s first dengue immunisation program recently in the Philippines. Recent studies have confirmed the vaccine’s consistent efficacy in reducing dengue due to all four serotypes. It has also been shown to prevent 8 out of 10 hospitalisations and up to 93% of severe dengue cases in those aged 9 and above.
Guillaume Leroy, of Sanofi Pasteur, says: “Introduction of the dengue vaccine first in endemic countries like Brazil has always been Sanofi Pasteur’s priority because this is where the vaccine can have the greatest impact on disease burden globally. Furthermore, successful implementation of Dengvaxia in a large-scale public program in Paraná will serve as a benchmark for dengue prevention efforts elsewhere in the country and in the world.”
Sean Murray
Related Content
BioNet receives positive EMA opinion on new pertussis vaccine
BioNet has received a positive opinion from the Committee for Medicinal Products for Human Use …
Recipharm offers manufacturing support to vaccine trial from ImmBIO and iiCON
Recipharm, a contract development and manufacturing organisation (CDMO), has successfully manufactured PnuBioVax, a new protein-based …
Sanofi and Regeneron’s Dupixent receives CHMP recommendation for chronic spontaneous urticaria
Sanofi and Regeneron have received a positive opinion from the European Medicines Agency’s (EMA) Committee …
